Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model
Open accessThe DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
The 2015 European pulmonary hypertension (PH) guidelines propose a risk stratification strategy for patients with pulmonary arterial hypertension (PAH). Low-, intermediate- and high-risk strata are defined by estimated 1-year mortality risks of <5%, 5–10% and >10%, respectively. This risk assessment strategy awaits validation. We analysed data from patients with newly diagnosed PAH enrolled into COMPERA (Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension), a European-based PH registry. An abbreviated version of the risk assessment strategy proposed by the European PH guidelines was applied, using the following variables: World Health Organization functional class, 6-min walking distance, brain natriuretic peptide or its N-terminal fragment, right atrial pressure, cardiac index and mixed venous oxygen saturation. Data from 1588 patients were analysed. Mortality rates were significantly different between the three risk strata (p<0.001 for all comparisons). In the entire patient population, the observed mortality rates 1 year after diagnosis were 2.8% in the low-risk cohort (n=196), 9.9% in the intermediate-risk cohort (n=1116) and 21.2% in the high-risk cohort (n=276). In addition, the risk assessment strategy proved valid at follow-up and in major PAH subgroups. An abbreviated version of the risk assessment strategy proposed by the current European PH guidelines provides accurate mortality estimates in patients with PAH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several European registries have since validated the ESC/ERS risk status model; however, it is unknown if the ESC/ERS tool predicts clinical worsening or hospitalizations.(288)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [288]
Citations
Cites
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citationAuthors/Task Force Members, Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J.-L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,846
Self-citationGaliè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
Self-citationMacitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Pulido, T., Adzerikho, I., Channick, R. N., Delcroix, M., Galiè, N., Ghofrani, H.-A., Jansa, P., Jing, Z.-C., Le Brun, F.-O., Mehta, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213917 · Cited by 1,443
Self-citationInitial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
Galiè, N., Barberà, J. A., Frost, A. E., Ghofrani, H.-A., Hoeper, M. M., McLaughlin, V. V., Peacock, A. J., Simonneau, G., Vachiery, J.-L., Grünig, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413687 · Cited by 1,182
Self-citationSelexipag for the Treatment of Pulmonary Arterial Hypertension
Sitbon, O., Channick, R., Chin, K. M., Frey, A., Gaine, S., Galiè, N., Ghofrani, H.-A., Hoeper, M. M., Lang, I. M., Preiss, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503184 · Cited by 1,060
Self-citationBenza, R. L., Gomberg-Maitland, M., Miller, D. P., Frost, A., Frantz, R. P., Foreman, A. J., Badesch, D. B., & McGoon, M. D. (2012) · Chest · doi:10.1378/chest.11-0676 · Cited by 557
Kylhammar, D., Kjellström, B., Hjalmarsson, C., Jansson, K., Nisell, M., Söderberg, S., Wikström, G., & Rådegran, G. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx257 · Cited by 540
Hoeper, M. M., Huscher, D., Ghofrani, H. A., Delcroix, M., Distler, O., Schweiger, C., Grunig, E., Staehler, G., Rosenkranz, S., Halank, M., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.10.026 · Cited by 466
Self-citationUpfront triple combination therapy in pulmonary arterial hypertension: a pilot study
Sitbon, O., Jaïs, X., Savale, L., Cottin, V., Bergot, E., Macari, E. A., Bouvaist, H., Dauphin, C., Picard, F., Bulifon, S., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00116313 · Cited by 382
Cited by
Items 401–500 of 739
Transforming Pulmonary Arterial Hypertension: Key Milestones and Future Perspectives
Humbert, M. J. C., Zeder, K., Kovács, G., & Weatherald, J. C. (2026) · Circulation · doi:10.1161/circulationaha.126.079274 · Cited by 6
Sun, Y., Wang, L., Meng, X., Gong, S., Zhao, Q., Shi, L., Jiang, R., He, J., Wu, W., Li, Y., et al. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-20-2732 · Cited by 6
“Venous blood samples were taken during RHC only for study purpose.”
BackgroundWu, S., & Wu, Y. (2022) · PubMed · doi:10.6515/acs.202203_38(2).20211005a · Cited by 6
Transplantation pulmonaire en France : actualisation des indications et contre-indications en 2022
Pavec, J. L., Pison, C. M., Hirschi, S., Bunel, V., Mordant, P., Brugière, O., Guen, M. L., Olland, A., Coiffard, B., Renaud-Picard, B., et al. (2022) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.10.005 · Cited by 6
Sonnweber, T., Tymoszuk, P., Steringer‐Mascherbauer, R., Sigmund, E., Porod-Schneiderbauer, S., Kohlbacher, L., Theurl, I., Lang, I. M., Weiß, G., & Löffler‐Ragg, J. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02427-2 · Cited by 6
“Mortality risk‐assessment tools The mortality risk at diagnosis was assessed by abbreviated versions of the ESC/ERS risk assessment tool: the three- and four parameter French Pulmonary Hypertension Registry scores (FPHR 3p and 4p), the Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPE…”
BackgroundMethodPulmonary hypertension: Proteins in the blood
Wilkins, M. R. (2020) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2020.7 · Cited by 6
Li, M., Tian, Z., Qian, J., Huang, C. L., Zhao, J., Wang, Q., Song, Y., Tian, X., Li, M., Liu, J., et al. (2022) · Lupus Science & Medicine · doi:10.1136/lupus-2021-000636 · Cited by 6
Gauthier‐Loiselle, M., Tsang, Y., Lefèbvre, P., Agron, P., Royer, J., Lynum, K. S. B., Bennett, L., & Panjabi, S. S. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2049162 · Cited by 6
Comentarios a la guía ESC/ERS 2022 sobre el diagnóstico y tratamiento de la hipertensión pulmonar
de la SEC, G. D. T. D. L. S. P. L. G. E. 2. S. E. D. Y. T. D. L. H. P. Y. C. D. G. (2023) · Revista Española de Cardiología · doi:10.1016/j.recesp.2022.10.015 · Cited by 6
Piloto, B. M., Fernandes, C. J. C. D. S., Jardim, C., Castro, M. A., Alves, J. L., & Souza, R. (2023) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20220337 · Cited by 6
“The concept of risk stratification is recent(11,13,14) and has not been used in order to determine response to”
Ostermann, J., Pott, J., Hennigs, J. K., Roedl, K., Sinning, C., Harbaum, L., & Klose, H. F. E. (2023) · ERJ Open Research · doi:10.1183/23120541.00072-2023 · Cited by 6
“A limitation of this three-strata risk-assessment model is that up to 70% of the patients are classified at intermediate risk [1, 8, 10].”
The haemodynamic assessment of patients with pulmonary arterial hypertension
Ghio, S. (2020) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2020.4 · Cited by 6
Sitbon, O., Reis, A., Humbert, M. J. C., Noordegraaf, A. V., & Delcroix, M. (2020) · European Respiratory Journal · doi:10.1183/13993003.01047-2020 · Cited by 6
Self-citationAssociation of PH-Targeted Therapy and Survival in Precapillary PH with mPAP between 21 and 24 mmHg
Yogeswaran, A., Fünderich, M., Olschewski, H., Kovács, G., Kiely, D. G., Lawrie, A., Hassoun, P. M., Balasubramanian, A., Konswa, Z., Pepke‐Żaba, J., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00466-2024 · Cited by 5
“In line, most of the patients were classified as intermediate risk, using the ESC/ERS 3-and 4-strata risk models, which are well established estimators of risk in PAH and CTEPH [21, 33, 44, 45].”
Self-citationBoutel, M., Dara, A., Arvanitaki, A., Deuteraiou, C., Mytilinaiou, M. G., & Dimitroulas, T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195834 · Cited by 5
“The prognosis for SSc-PAH is generally dismal, as it remains alarmingly high compared to that of idiopathic PAH [16,45,46].”
BackgroundPentikäinen, M. O., Simonen, P. P., Leskelä, P., Harju, T. H., Jääskeläinen, P., Wennerström, C., Bødker, N., Heikkilä, E., Lahelma, M., Leskelä, R., et al. (2024) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2024.101534 · Cited by 5
“The five-year survival rate for PAH varies by baseline risk and treatment, estimated between 32 and 76 % [3].”
BackgroundDardi, F., Guarino, D., Ballerini, A., Bertozzi, R., Donato, F., Cennerazzo, F., Salvi, M., Nardi, E., Magnani, I., Manes, A., et al. (2025) · ERJ Open Research · doi:10.1183/23120541.01353-2024 · Cited by 5
Santos, R. T., Braga, C. L., Onofre, M. E. D. S. F., da Silva, C. M., Rocha, N. N., Veras, R. G., Serra, S. S. D. S., Teixeira¹, D. E., Alves, S. A. S., de Miranda, B. T., et al. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04604-y · Cited by 5
“Despite these findings, the impact of MSC-derived EVs on cardiac remodeling in PAH remains largely unexplored, even though heart failure is the leading cause of mortality in patients with PAH [25].”
Wang, A.-Y., Ma, J., Cui, Y., Qiu, B., Liu, C., Lü, D., Yang, Y.-J., Zhou, Y., Zhang, Z., Xu, X.-Q., et al. (2025) · CHEST Journal · doi:10.1016/j.chest.2025.10.031 · Cited by 5
Palliative Care Issues in Pulmonary Arterial Hypertension #367
Chandrasekhar, M. A., Rao, A., Ruiz, G., & Groninger, H. (2019) · Journal of Palliative Medicine · doi:10.1089/jpm.2018.0618 · Cited by 5
Gratsianskaya, S. E., Солтановна, В. З., & Martynyuk, T. V. (2020) · Terapevticheskii arkhiv · doi:10.26442/00403660.2020.09.000717 · Cited by 5
Huai, X., Sun, Y., Xiuying, S., Wu, W., Wang, L., Jiang, R., Gong, S., Li, J., Miao, Y., Yuan, P., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-2479 · Cited by 5
“Studies have shown that FFAs, also called non-esterified fatty acids, as intermediate products of lipid metabolism in the blood, are important metabolic substrates of cell energy metabolism in the body, providing energy for the metabolism of heart, liver, skeletal muscle, and other organs (14).”
BackgroundMartynyuk, T. V., & Chazova, I. E. (2021) · Terapevticheskii arkhiv · doi:10.26442/00403660.2021.09.201013 · Cited by 5
“АПФ-2 – ангиотензинпревращающий фермент 2 ВОЗ – Всемирная организация здравоохранения ВПС – врожденный порок сердца ДЗЛА – давление заклинивания в легочной артерии ДИ – доверительный интервал ДЛА – давление в легочной артерии Д6МХ – дистанция в тесте 6-минутной ходьбы ИЛГ – идиопатическая легочная гипертензия иФДЭ-5 –…”
InfluentialPredictive value of chest HRCT for survival in idiopathic pulmonary arterial hypertension
Kacprzak, A., Burakowska, B., Kurzyna, M., Fijałkowska, A., Florczyk, M., Wieteska, M., Darocha, S., Torbicki, A., & Szturmowicz, M. (2021) · Respiratory Research · doi:10.1186/s12931-021-01893-8 · Cited by 5
“The 1,2,3-year survival rates in the cGGO group were similar to those reported for high-risk group PAH patients in national and international registries [20, 22], although only 17% of cGGO patients were in the high-risk group at the baseline assessment.”
ResultQuan, R., Huang, S., Pang, L., Shen, J., Wu, W., Tang, F., Zhu, X., Su, W., Sun, J., Yu, Z., et al. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02492-1 · Cited by 5
Diagnostic and prognostic value of ventilatory power in pulmonary hypertension
Li, X., Zhang, Y., Jin, Q., Zhao, Z., Zhao, Q., Lu, Y., Duan, A., Huang, Z., Hu, M., Xiong, C., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-02212-5 · Cited by 5
“Risk stratification strategy We used the abbreviated 2015 ESC/ERS risk stratification strategy to categorize patients as low, intermediate or high risk [9].”
MethodXing, C., Wang, X., Pan, X., Yu, J., Wang, C., Li, Y., Shen, L., & He, B. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.12.002 · Cited by 5
Yang, G., He, Y., Lv, Y., Chen, Y., Coatrieux, J.-L., Sun, X., Wang, Q., Wei, Y., Li, S., & Zhu, Y. (2023) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2023.3247492 · Cited by 5
“CTD-PAH is a rare subtype of PAH and 140 is a comparable amount as the related works (162) [33], (347) [34].”
BackgroundMeñaca, A. M., Cruz‐Utrilla, A., Cuesta, V. M. M., Luna‐López, R., de la Cal, T. S., Camacho, Á. F., Alonso‐Lecue, P., Subías, P. E., & Martínez, J. M. C. (2024) · Pulmonary Circulation · doi:10.1002/pul2.12342 · Cited by 5
Boxhammer, E., Mirna, M., Bäz, L., Alushi, B., Franz, M., Kretzschmar, D., Hoppe, U. C., Lauten, A., & Lichtenauer, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11112978 · Cited by 5
Sharma, D., Shah, R. J., Sreenivasan, J., Kafle, P., Gupta, R., Levine, A., Lanier, G. M., & Aronow, W. S. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2092095 · Cited by 5
“COMPERA and SPAHR assess RA pressure, CI and SvO2 and FPHN uses RA pressure and cardiac output (CO) [4].”
BackgroundInfluentialWißmüller, M., Wartner, V., Hohmann, C., Adler, J., Kramer, T., Hellmich, M., Gerhardt, F., Baldus, S. E., & Rosenkranz, S. (2023) · European Respiratory Journal · doi:10.1183/13993003.01454-2022 · Cited by 5
Self-citationBenza, R. L., Lickert, C. A., Xie, L., Drake, W., Ogbomo, A. S., Yüce, H., & Cole, M. R. (2020) · Pulmonary Circulation · doi:10.1177/2045894020954158 · Cited by 5
Subías, P. E., Pérez, Á. A., Pérez‐Olivares, C., Climent, L. G., Diago, J. I., & Perelló, M. F. (2021) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2021.1878027 · Cited by 5
“Since then, subsequent studies with this combination have provided further evidence related to other topics discussed CONTACT Pilar Escribano Subías pilar.escribano.subias@gmail.com Pulmonary Hypertension Unit, Cardiology Department, Hospital Universitario12 De Octubre, Av. Córdoba, S/n, 28041 Madrid, Spain © 2021 Inf…”
MethodInfluentialRiociguat in the Treatment of Pulmonary Arterial Hypertension
Jerjes-Sánchez, C., Valdez-López, H. G., Zayas, N., Cueto‐Robledo, G., Bonola, L., Pech-Alonso, B., Ramírez, A., Flores-Puente, F., García‐Aguilar, H., Hernández, G. E., et al. (2022) · Archives of Medical Research · doi:10.1016/j.arcmed.2022.04.001 · Cited by 5
Sanna, L., & Todea, A. R. (2022) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2022.100893 · Cited by 5
Harutyunova, S., Benjamin, N., Eichstaedt, C. A., Marra, A. M., Xanthouli, P., Nagel, C., Grünig, E., & Egenlauf, B. (2023) · Respiration · doi:10.1159/000531169 · Cited by 5
Self-citationIannuzzi, G. L., D’Alto, M., Formisano, R., & Maniscalco, M. (2019) · Biomarkers in Medicine · doi:10.2217/bmm-2018-0491 · Cited by 5
Middleton, J. T., Binmahfooz, S., Zafar, H., Patel, J., Ashraf, C., Jake, Neelam-Naganathan, D., Battersby, C., Pearson, C., Roddis, C., et al. (2023) · medRxiv · doi:10.1101/2023.04.27.23289153 · Cited by 5
Treatment Response and Survival in Methamphetamine‐Associated Pulmonary Arterial Hypertension
Uhland, C., Gibbs, A., Insel, M. B., Kubba, S., & Rischard, F. P. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.042673 · Cited by 4
The Prognostic Value of 18F-FAPI PET/CT Imaging in Pulmonary Arterial Hypertension
Chen, H.-M., Hou, P., Liang, S.-H., Guo, W., Sun, T.-T., Zhong, S.-N., Zhong, K.-X., Zhao, R.-Y., Fu, Y., Zhong, H., et al. (2026) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2025.11.010 · Cited by 4
D’Alto, M., Scelsi, L., Giuliani, L., Perna, G. P., Baldi, F., Guerra, F., Poi, E. D., Vicenzi, M., Badagliacca, R., Corda, M., et al. (2026) · Vascular Pharmacology · doi:10.1016/j.vph.2026.107585 · Cited by 4
Marqués, R. B., Becerra‐Muñoz, V. M., Espíldora-Hernández, F., & Mayoral, A. R. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.04.010 · Cited by 4
Weiss, T., Ramey, D. R., Pham, N., Shaikh, N. F., Tian, D., Zhao, X., Near, A. M., Lautsch, D., & Nathan, S. D. (2024) · Pulmonary Circulation · doi:10.1002/pul2.12390 · Cited by 4
Jumatate, R., Evaldsson, A. W., Ingvarsson, A., Rådegran, G., Meurling, C., & Ostenfeld, E. (2024) · European Heart Journal - Imaging Methods and Practice · doi:10.1093/ehjimp/qyae128 · Cited by 4
“This mortality is in alignment with national registries 40–44 and highlights that PAH prognosis remains poor and the high importance of optimizing treatment strategies and better timing for lung transplant.”
Utility of Clustering in Mortality Risk Stratification in Pulmonary Hypertension
Tondo, P., Tricarico, L., Galgano, G., Varlese, M. P. C., Aruanno, D., Gallo, C., Scioscia, G., Brunetti, N. D., Correale, M., & Lacedonia, D. (2025) · Bioengineering · doi:10.3390/bioengineering12040408 · Cited by 4
“Other risk-stratification tools have been developed from the US REVEAL (i.e., REVEAL 2.0 risk score calculator and REVEAL Lite 2) [36,38].”
InfluentialKhanzadeh, S., Aminizadeh, S., Nourigheimasi, S., Lucke-Wold, B. P., Rashidi, F., Kaymaz, C., Janda, P., Reis, A., Goutnik, M., Khanzadeh, M., et al. (2025) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v42i2.14552 · Cited by 4
“In our review study, the study by Mirsaeidi (23) was conducted on USA population with EF>40 mmHg; while the study by Korkmaz (21) contained Turkey patients with higher stages of SSs (2,3, and 4).”
Qaderi, V., Weimann, J., Harbaum, L., Schrage, B., Knappe, D., Hennigs, J. K., Sinning, C., Schnabel, R. B., Blankenberg, S., Kirchhof, P. F., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215130 · Cited by 4
“While previous models usually aimed to predict the one year outcome [1,6,8,9], our results relevantly contribute to the horizon of risk assessment.”
MethodResultSinkala, E., Ahmed, H. Y., Sibomana, J. P., Lee, M. H., Kassa, B., Kumar, R., Mazimba, S., Binegdie, A. B., Mpisa, S., Kawana, W., et al. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12072 · Cited by 4
Lange, T. J. (2023) · Herz · doi:10.1007/s00059-023-05179-1 · Cited by 4
Dardi, F., Guarino, D., Cennerazzo, F., Ballerini, A., Magnani, I., Bertozzi, R., Donato, F., Martini, G., Manes, A., Galiè, N., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103425 · Cited by 4
Impact of Parenteral Prostanoids in Pulmonary Arterial Hypertension: The Relevance of Timing
Papa, S., Scoccia, G., Serino, G., Adamo, F. I., Jabbour, J. P., Caputo, A., Boromei, M., Filomena, D., Laviola, D., Maggio, E., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216840 · Cited by 4
Self-citationBrown, Z., Hansen, D., Stevens, W., Ferdowsi, N., Ross, L., Quinlivan, A., Sahhar, J., Ngian, G., Apostolopoulos, D., Walker, J. G., et al. (2024) · Arthritis Care & Research · doi:10.1002/acr.25328 · Cited by 4
Brownstein, A. J., Cooper, C. B., Jasuja, S., Sherman, A. E., Saggar, R., & Channick, R. N. (2024) · CHEST Pulmonary · doi:10.1016/j.chpulm.2024.100059 · Cited by 4
“Given the prognostic signi fi cance of CI in patients with PH and its importance for both risk strati fi cation and determining the need for escalation of PH therapy, 25-28 an accurate measurement of CI is critical.”
The effects of oxygenation on acute vasodilator challenge in pulmonary arterial hypertension
Rockstrom, M. D., Jin, Y., Peterson, R., Hountras, P., Badesch, D. B., Gu, S., Park, B., Messenger, J. C., Forbes, L. M., Cornwell, W. K., et al. (2024) · Pulmonary Circulation · doi:10.1002/pul2.12375 · Cited by 4
van Dissel, A. C., D’Alto, M., Farro, A., Mathijssen, H., Post, M. C., Bassareo, P. P., van Dijk, A. P. J., Mulder, B. J. M., & Bouma, B. J. (2024) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2024.08.027 · Cited by 4
Risk assessment models and survival in pulmonary arterial hypertension: A SPAHR analysis
Hjalmarsson, C., Thakur, T., Weiss, T., Björklund, E., Papageorgiou, J., Rådegran, G., Söderberg, S., Wåhlander, H., Lautsch, D., & Kjellström, B. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.10.029 · Cited by 4
Vaidya, A., Sketch, M. R., Broderick, M. J., & Shlobin, O. A. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03388-w · Cited by 4
Refining Prognostication and Therapeutic Guidance Through Advances in Right Heart Imaging Approaches
Mombeini, H., Mercurio, V., Osgueritchian, R., Grapsa, J., Kim, J. J., & Mukherjee, M. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.03.002 · Cited by 4
Wan, C., Chen, M., Tong, J., Wang, A., Ruan, B., & Shen, J. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133347 · Cited by 4
de la Fuente, A., Zagolín, M., Parra, V., Paz, A. A., González‐Candia, A., Cabrera, O., Cristián Olave, C., Bahamondes, C., Gaete, M. J., Gudenschwager, L., et al. (2025) · Pulmonary Circulation · doi:10.1002/pul2.70109 · Cited by 4
“However, this condition is still progressive and with an averaged survival of 86% at 1 year [3] and 35% after 5 years [6], so novel therapeutic approaches are urgently needed.”
Hassan, H. J., Naranjo, M., Kazzi, B. E., Housten-Harris, T., Hsu, S., Balasubramanian, A., Simpson, C. E., Damico, R. L., Kolb, T. M., Mathai, S. C., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.00801-2022 · Cited by 4
Grześk, G., Karasek, D., & Kusiak, M. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000806 · Cited by 4
Hsu, J. Y., Major, J. L., Riching, A. S., Sen, R., Silva, J. P. D., & Bagchi, R. A. (2020) · Biochemistry and Cell Biology · doi:10.1139/bcb-2020-0039 · Cited by 4
Imai, R., Adachi, S., Yoshida, M., Shimokata, S., Nakano, Y., Okumura, N., Murohara, T., & Kondo, T. (2020) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2019-0640 · Cited by 4
Prediction Models and Scores in Pulmonary Hypertension: A Review
Mouratoglou, S., Bayoumy, A. A., & Noordegraaf, A. V. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612824999201105163437 · Cited by 4
Windsor, J., Mukundan, C., Stopak, J. K., & Ramakrishna, H. (2021) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2021.04.006 · Cited by 4
Akaslan, D., Aslanger, E. K., Ataş, H., Kocakaya, D., Yıldızeli, B., & Mutlu, B. (2023) · Balkan Medical Journal · doi:10.4274/balkanmedj.galenos.2023.2023-2-22 · Cited by 4
Risk assessment in patients with systemic sclerosis and pulmonary arterial hypertension
Olsson, K. M., & Hoeper, M. M. (2018) · European Respiratory Journal · doi:10.1183/13993003.01745-2018 · Cited by 4
Self-citationGaliè, N., Palazzini, M., & Manes, A. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad672 · Cited by 4
Yasuhara, J., Watanabe, K., Watanabe, A., Shirasu, T., Matsuzaki, Y., Watanabe, H., Takagi, H., Sumitomo, N., & Kuno, T. (2023) · Cardiology in the Young · doi:10.1017/s1047951123000124 · Cited by 3
Asano, R., Nagase, S., Aoki, T., Ueda, J., Tsuji, A., Asakura, K., Fukuda‐Doi, M., Inoue, Y. Y., KUSANO, K. F., Yamamoto, H., et al. (2025) · Circulation Reports · doi:10.1253/circrep.cr-24-0179 · Cited by 3
SUL-150 Limits Vascular Remodeling and Ventricular Failure in Pulmonary Arterial Hypertension
Jorna, L. M., Nakládal, D., van Heuveln, J. N., van der Feen, D. E., Hagdorn, Q. A. J., Bossers, G. P. L., van Oosten, A., Weij, M., Tkáčiková, Ľ., Tkáčiková, S., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157181 · Cited by 3
“Right ventricular failure due to its increased afterload is the main contributor to mortality in PAH patients [4].”
Lyapina, I. N., Солтановна, В. З., Андреевна, Б. А., Saidova, M. A., Martynyuk, T. V., & Chazova, I. E. (2021) · Terapevticheskii arkhiv · doi:10.26442/00403660.2021.03.200655 · Cited by 3
“При этом у когорты пациентов с ЛАГ и низким риском уровень смертности в течение года достигает 2,8%, у пациентов с промежуточным риском – 9,9% и с высоким риском – 21,2% [23].”
Endobronchial Gene Delivery for Pulmonary Hypertension in a Large Animal Model
Bikou, O., & Ishikawa, K. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2707-5_21 · Cited by 3
Luo, J., Sun, J., Xu, L., Chen, J., Chen, Y., Chen, W., Qiu, H., Luo, X.-Q., Chen, S., & Li, J. (2023) · Journal of Electrocardiology · doi:10.1016/j.jelectrocard.2023.08.002 · Cited by 3
Allgemeine Maßnahmen und Management der pulmonalarteriellen Hypertonie
Lichtblau, M., Harutyunova, S., Nechwatal, R., Mayer, L. C., Kabitz, H., Wilkens, F. M., Uiker, S., Grünig, E., Ritter, D., Florea, A., et al. (2023) · Pneumologie · doi:10.1055/a-2145-4741 · Cited by 3
“Gemäß Registerdaten werden ca. 43 % der Patient*innen mit idiopathischer PAH mit Antikoagulanzien behandelt [8].”
BackgroundSelf-citationCorrêa, R. D. A., Rezende, C. F., Mancuzo, E. V., Mickael, C. S., Loureiro, C. M. C., Oliveira, R. K. F., Hilton, J. F., & Graham, B. B. (2025) · Pulmonary Circulation · doi:10.1002/pul2.70086 · Cited by 3
“The COMPERA 3 ‐ level risk score was calculated at admission [11], adapted from the risk assessment instrument from the 2015 ESC/ERS guidelines [1].”
InfluentialPulmonary Hypertension and Lung Transplantation
Kruszona, S., Aburahma, K., de Manna, N. D., Bobylev, D., Ruhparwar, A., Kuehn, C., Salman, J., & Ius, F. (2025) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/a-2590-2620 · Cited by 3
“…for continuing pretransplant ECMO support and extending ECMO support directly in the posttransplant period; the possibility of performing major cardiac surgery, for example coronary artery bypass grafting (CABG); the lower amount of heparin (usually a single 5000 IU bolus of unfractionated…”
Conde‐Camacho, R., Orozco‐Levi, M., Londoño, A., Gómez-Paláu, R., Tuta-Quintero, E., Naranjo, A., Díaz-Martínez, K., Luque, J. D., Goldfeder, S., Giraldo‐Cadavid, L. F., et al. (2025) · Pulmonary Circulation · doi:10.1002/pul2.70145 · Cited by 3
“Patients are categorized into low ‐ , intermediate ‐ , or high ‐ risk groups, corresponding to estimated 1 ‐ year mortality rates of < 5%, 5% – 10%, and > 10%, respectively [7 – 9].”
Diagnosis of pulmonary arterial hypertension: a statement from the Brazilian Thoracic Association
Alves-Jr1, J. L., Amado, V. M., Correa3, R. A., Campos, F. T. A. F., Fernandes, C. J. C. D. S., Ferreira, E. V. M., Gazzana, M. B., Rocha, M. J. J., Jardim, C., Arakaki, J. S. O., et al. (2025) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20250065 · Cited by 3
“(69,70) Patients can be classified by attributing values of 1 to low risk, 2 to intermediate risk, and 3 to high risk for each variable, according to their values, and calculating the arithmetic mean (the sum of points divided by the number of criteria evaluated).”
Li, X., Zhang, Y., Zhao, Q., Yang, T., Zeng, Q., Jin, Q., Duan, A., Huang, Z., Hu, M., Zhang, S., et al. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2358745 · Cited by 3
“To compare different risk stratifications in predicting hemodynamic outcomes, we used the following risk assessment tools: [20], and laboratory models [21].”
MethodYogeswaran, A., da Rocha, B. R. B., Rako, Z. A., Kaufmann, S. J., Schäfer, S., Kremer, N., Ghofrani, H. A., Seeger, W., & Tello, K. (2024) · Scientific Reports · doi:10.1038/s41598-024-61825-6 · Cited by 3
“RV diastolic function during exertion was significantly impaired in patients with impaired RAP variation (RV end-diastolic pressure: 16 [10, 25] mm Hg vs 12 [7, 17] mm Hg, P = 0.049; Eed: 0.36 [0.28, 0.51] mm Hg/mL vs 0.27 [0.12, 0.45] mm Hg/mL, P = 0.012).”
BackgroundInfluentialSelf-citationBichuette, L. D., Calderaro, D., Neto, P. A. L., Fonseca, E. K. U. N., Tatagiba, L. S., Vieira, T. M., Nascimento, Y. P. P., Castro, M. A., Silva, T. A. F., Parente, Y. D. D. M., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250002i · Cited by 3
Bichuette, L. D., Calderaro, D., Lemos, P. A., Fonseca, E. K. U. N., Tatagiba, L. S., Vieira, T. M., Nascimento, Y. P. P., Castro, M. A., da Silva, T. A. F., Parente, Y. D. D. M., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250002 · Cited by 3
Araujo, J. J. (2020) · International Journal of Clinical Cardiology · doi:10.23937/2378-2951/1410190 · Cited by 3
Wernhart, S., & Hedderich, J. (2020) · JRSM Cardiovascular Disease · doi:10.1177/2048004020973834 · Cited by 3
“Non invasive parameters of mortality risk stratification in pulmonary arterial hypertension (PAH) and PH have been established and have been validated in other cohorts.(3,4) Recently, hypochloremia has been suggested as a non-invasive marker to predict one, three- and fiveyear-survival in PH.”
BackgroundPrognostic Value of Early Risk Stratification in Pediatric Pulmonary Arterial Hypertension
Ablonczy, L., Ferenci, T., Somoskövi, O., Osváth, R., Reusz, G., & Kis, É. (2021) · Transplantation Proceedings · doi:10.1016/j.transproceed.2021.01.047 · Cited by 3
A novel electrocardiogram characteristic in patients with myocardial injury due to COVID-19
Chenaghlou, M., Mirtajaddini, M., & Salehi, R. (2021) · Research in Cardiovascular Medicine · doi:10.4103/rcm.rcm_21_21 · Cited by 3
Ho, W., Lin, C., Hsu, L., & Wang, C. (2022) · Respiratory Case Reports · doi:10.5505/respircase.2022.55476 · Cited by 3
Sarcoidosis-associated pulmonary hypertension
Khangoora, V. S., Nunès, H., & Shlobin, O. A. (2022) · European Respiratory Society eBooks · doi:10.1183/2312508x.10032920 · Cited by 3
Hospitalisation Is Prognostic of Survival in Chronic Thromboembolic Pulmonary Hypertension
Jansa, P., Ambrož, D., Aschermann, M., Černý, V., Dytrych, V., Heller, S., Kunstýř, J., Lindner, J., Linhart, A., Nižňanský, M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206189 · Cited by 3
“Most had severe disease at diagnosis as shown by the New York Heart Association functional classification (NYHA FC), 6-minute walk distance (6MWD), and haemodynamic parameters [12,15].”
MethodCombination therapy of newly diagnosed intermediate-risk pulmonary arterial hypertension: A review
Lyapina, I. N., Zvereva, T. N., & Martynyuk, T. V. (2022) · Consilium Medicum · doi:10.26442/20751753.2022.10.201875 · Cited by 3
“В когорте пациентов с ЛАГ и низким риском уровень смертности в течение 1 года достигает 2,8%, у пациентов с промежуточным риском – 9,9% и с высоким риском – 21,2% [12].”
Hypertension Multi-Year Prediction and Risk Factors Analysis Using Decision Tree
Gozali, A. A. (2023) · International Conference on Information Technology, Computer, and Electrical Engineering · doi:10.1109/icitacee58587.2023.10277644 · Cited by 3
“Early detection and prediction of hypertension are essential for effectively managing and preventing hypertension-related complications [4], [5].”
BackgroundPapadopoulos, G. E., Arvanitaki, A., Markidis, E., Mouratoglou, S., Farmakis, I. T., Gourgiotis, P., Chrysochoidis‐Trantas, T., Feloukidis, C., Κouparanis, A., Didagelos, M., et al. (2023) · Life · doi:10.3390/life13112225 · Cited by 3
Chen, C., Wang, M.-T., Sung, S., Wu, Y., Hsu, C., Ho, W., Lin, Y., Liu, W.-S., Liu, J., Kao, Y., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27537 · Cited by 3
Kaymaz, C., Akbal, Ö. Y., Hakgör, A., Tokgöz, H. C., & Tanyeri, S. (2018) · Pulmonary Circulation · doi:10.1177/2045894018780522 · Cited by 3
“2% in the low-risk, intermediate-risk, and high- risk cohorts, respectively.(37) In the French registry including the incident patients with idiopathic, heritable, or drug-induced PAH, the low-risk criteria derived from four variables (FC I or II, 6MWD> 440m, mRAP< 8mmHg, and CI 2.”
BackgroundSpießhoefer, J., Bannwitz, B., Möhr, M., Herkenrath, S. D., Randerath, W. J., Sciarrone, P., Thiedemann, C., Schneider, H., Braun, A. T., Emdin, M., et al. (2020) · Sleep And Breathing · doi:10.1007/s11325-020-02159-1 · Cited by 3
Sequential combination therapy with parenteral prostacyclin in BMPR2 mutations carriers
Boucly, A., Savale, L., Jaïs, X., Humbert, M. J. C., Sitbon, O., & Montani, D. (2021) · Pulmonary Circulation · doi:10.1002/pul2.12023 · Cited by 3
“In addition, after prostacyclin initiation all patients carrying a BMPR2 mutation achieved a low‐risk status according to COMPERA methodology.(4) Our results in a larger series of idiopathic and heritable PAH do not validate the conclusions of a lower response to prostanoids in PAH patients carrying a BMPR2 mutation a…”
ResultHighlights from the ERS International Congress 2018: Assembly 13 – Pulmonary Vascular Diseases
Ramjug, S., Adão, R., Lewis, R. A., Coste, F., de Man, F. S., Jiménez, D., Sitbon, O., Delcroix, M., & Noordegraaf, A. V. (2019) · ERJ Open Research · doi:10.1183/23120541.00202-2018 · Cited by 3
Self-citation
Metadata
- Authors
- Hoeper, M. M., Kramer, T., Pan, Z., Eichstaedt, C. A., Spiesshoefer, J., Benjamin, N., Olsson, K. M., Meyer, K., Vizza, C. D., Vonk-Noordegraaf, A., Distler, O., Opitz, C., Gibbs, J. S. R., Delcroix, M., Ghofrani, H. A., Huscher, D., Pittrow, D., Rosenkranz, S., & Grünig, E.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- University of Cologne (DE)
- University Hospital Heidelberg (DE)
- Heinrich Heine University Düsseldorf (DE)
- Sapienza University of Rome (IT)
- University Hospital Zurich (CH)
- DRK Kliniken Berlin (DE)
- Imperial College London (GB)
- Universitair Ziekenhuis Leuven (BE)
- Justus-Liebig-Universität Gießen (DE)
- Technische Universität Dresden (DE)
- ORCID
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2017-08
- Volume
- 50
- Issue
- 2
- Pages
- 1700740
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2743897368
- Cited by
- 660
- References
- 21
- Citations by year
- 2026: 21 · 2025: 52 · 2024: 74 · 2023: 84 · 2022: 101 · 2021: 111 · 2020: 92 · 2019: 63 · 2018: 53 · 2017: 8
- FWCI
- 48.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Respiratory Journal (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- GlaxoSmithKline
- German Centre of Lung Research
- Bayer
- Actelion Pharmaceuticals
- Deutsche Forschungsgemeinschaft (HO 1599/2-1)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- pulmonary arterial hypertension, mortality prediction, risk stratification, one-year mortality, functional class, 6-minute walk distance, brain natriuretic peptide, right atrial pressure, cardiac index, mixed venous oxygen saturation
- MeSH terms
- Walk Test, Adult, Aged, Aged, 80 and over, Europe, Female, Hemodynamics, Humans, Hypertension, Pulmonary, Male, Middle Aged, Prospective Studies, Registries, Severity of Illness Index, Practice Guidelines as Topic, Risk Assessment, Natriuretic Peptide, Brain, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.